Connection

Denis Guttridge to Humans

This is a "connection" page, showing publications Denis Guttridge has written about Humans.
Connection Strength

0.683
  1. Cancer cachexia: involvement of an expanding macroenvironment. Cancer Cell. 2023 03 13; 41(3):581-584.
    View in: PubMed
    Score: 0.033
  2. Emerging signaling mediators in the anorexia-cachexia syndrome of cancer. Trends Cancer. 2022 05; 8(5):397-403.
    View in: PubMed
    Score: 0.031
  3. Modeling Human Cancer-induced Cachexia. Cell Rep. 2019 08 06; 28(6):1612-1622.e4.
    View in: PubMed
    Score: 0.026
  4. Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-na?ve pancreatic cancer patients. J Cachexia Sarcopenia Muscle. 2018 04; 9(2):358-368.
    View in: PubMed
    Score: 0.023
  5. Dysregulated Myogenesis in Rhabdomyosarcoma. Curr Top Dev Biol. 2018; 126:285-297.
    View in: PubMed
    Score: 0.023
  6. Inflammation induced loss of skeletal muscle. Bone. 2015 Nov; 80:131-142.
    View in: PubMed
    Score: 0.020
  7. A TGF-? pathway associated with cancer cachexia. Nat Med. 2015 Nov; 21(11):1248-9.
    View in: PubMed
    Score: 0.020
  8. Impaired regeneration: A role for the muscle microenvironment in cancer cachexia. Semin Cell Dev Biol. 2016 06; 54:82-91.
    View in: PubMed
    Score: 0.020
  9. Inflammation based regulation of cancer cachexia. Biomed Res Int. 2014; 2014:168407.
    View in: PubMed
    Score: 0.018
  10. NF-?B-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J Clin Invest. 2013 Nov; 123(11):4821-35.
    View in: PubMed
    Score: 0.017
  11. Mechanisms of impaired differentiation in rhabdomyosarcoma. FEBS J. 2013 Sep; 280(17):4323-34.
    View in: PubMed
    Score: 0.017
  12. miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR. Sci Signal. 2013 Jul 30; 6(286):ra63.
    View in: PubMed
    Score: 0.017
  13. Reining in nuclear factor-kappaB in skeletal muscle disorders. Curr Opin Clin Nutr Metab Care. 2013 May; 16(3):251-7.
    View in: PubMed
    Score: 0.017
  14. Mechanisms for maintaining muscle. Curr Opin Support Palliat Care. 2012 Dec; 6(4):451-6.
    View in: PubMed
    Score: 0.016
  15. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012 Aug 08; 16(2):153-66.
    View in: PubMed
    Score: 0.016
  16. Making muscles grow by g protein-coupled receptor signaling. Sci Signal. 2011 Nov 29; 4(201):pe45.
    View in: PubMed
    Score: 0.015
  17. NF-?B signaling in skeletal muscle health and disease. Curr Top Dev Biol. 2011; 96:85-119.
    View in: PubMed
    Score: 0.014
  18. TNF inhibits Notch-1 in skeletal muscle cells by Ezh2 and DNA methylation mediated repression: implications in duchenne muscular dystrophy. PLoS One. 2010 Aug 30; 5(8):e12479.
    View in: PubMed
    Score: 0.014
  19. microRNAs: novel components in a muscle gene regulatory network. Cell Cycle. 2009 Jun 15; 8(12):1833-7.
    View in: PubMed
    Score: 0.013
  20. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell. 2008 Nov 04; 14(5):369-81.
    View in: PubMed
    Score: 0.012
  21. Skeletal muscle diseases, inflammation, and NF-kappaB signaling: insights and opportunities for therapeutic intervention. Int Rev Immunol. 2008; 27(5):375-87.
    View in: PubMed
    Score: 0.012
  22. NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol Cell Biol. 2007 Jun; 27(12):4374-87.
    View in: PubMed
    Score: 0.011
  23. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest. 2007 Apr; 117(4):889-901.
    View in: PubMed
    Score: 0.011
  24. Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome. Clin Cancer Res. 2007 Mar 01; 13(5):1356-61.
    View in: PubMed
    Score: 0.011
  25. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell. 2005 Nov; 8(5):421-32.
    View in: PubMed
    Score: 0.010
  26. Signaling pathways weigh in on decisions to make or break skeletal muscle. Curr Opin Clin Nutr Metab Care. 2004 Jul; 7(4):443-50.
    View in: PubMed
    Score: 0.009
  27. Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products. J Biol Chem. 2003 Jan 24; 278(4):2294-303.
    View in: PubMed
    Score: 0.008
  28. Editorial: Highlights from the 2020 virtual cancer cachexia conference. Curr Opin Support Palliat Care. 2021 03 01; 15(1):48-49.
    View in: PubMed
    Score: 0.007
  29. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999 Aug; 19(8):5785-99.
    View in: PubMed
    Score: 0.006
  30. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Pancreatology. 2019 Jan; 19(1):80-87.
    View in: PubMed
    Score: 0.006
  31. The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced Cachexia. Cancer Res. 2018 12 01; 78(23):6680-6690.
    View in: PubMed
    Score: 0.006
  32. SAMHD1 suppresses innate immune responses to viral infections and inflammatory stimuli by inhibiting the NF-?B and interferon pathways. Proc Natl Acad Sci U S A. 2018 04 17; 115(16):E3798-E3807.
    View in: PubMed
    Score: 0.006
  33. Cancer-associated cachexia. Nat Rev Dis Primers. 2018 01 18; 4:17105.
    View in: PubMed
    Score: 0.006
  34. Perioperative cytokine levels portend early death after pancreatectomy for ductal adenocarcinoma. J Surg Oncol. 2018 May; 117(6):1260-1266.
    View in: PubMed
    Score: 0.006
  35. Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models. Pediatr Blood Cancer. 2018 Feb; 65(2).
    View in: PubMed
    Score: 0.006
  36. Predictors of Pancreatic Cancer-Associated Weight Loss and Nutritional Interventions. Pancreas. 2017 10; 46(9):1152-1157.
    View in: PubMed
    Score: 0.006
  37. NF?B signaling in alveolar rhabdomyosarcoma. Dis Model Mech. 2017 09 01; 10(9):1109-1115.
    View in: PubMed
    Score: 0.006
  38. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS One. 2017; 12(7):e0181885.
    View in: PubMed
    Score: 0.006
  39. Enhancing the Cell Permeability and Metabolic Stability of Peptidyl Drugs by Reversible Bicyclization. Angew Chem Int Ed Engl. 2017 02 01; 56(6):1525-1529.
    View in: PubMed
    Score: 0.005
  40. Ken Fearon. Cell Metab. 2016 12 13; 24(6):765-766.
    View in: PubMed
    Score: 0.005
  41. Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. Mol Cancer Ther. 2017 02; 16(2):344-356.
    View in: PubMed
    Score: 0.005
  42. Characterization of the human protease nexin-1 promoter and its regulation by Sp1 through a G/C-rich activation domain. J Neurochem. 1996 Aug; 67(2):498-507.
    View in: PubMed
    Score: 0.005
  43. Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia. Cancer Discov. 2016 09; 6(9):1036-51.
    View in: PubMed
    Score: 0.005
  44. The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Mol Cancer Ther. 2016 05; 15(5):1018-28.
    View in: PubMed
    Score: 0.005
  45. A selective screening platform reveals unique global expression patterns of microRNAs in a cohort of human soft-tissue sarcomas. Lab Invest. 2016 Apr; 96(4):481-91.
    View in: PubMed
    Score: 0.005
  46. Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-?B-dependent Manner. Cancer Cell. 2016 Feb 08; 29(2):201-13.
    View in: PubMed
    Score: 0.005
  47. Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target. FASEB J. 2015 Nov; 29(11):4544-54.
    View in: PubMed
    Score: 0.005
  48. Cancer cachexia update in head and neck cancer: Pathophysiology and treatment. Head Neck. 2015 Jul; 37(7):1057-72.
    View in: PubMed
    Score: 0.005
  49. Rhabdomyosarcoma: current challenges and their implications for developing therapies. Cold Spring Harb Perspect Med. 2014 Nov 03; 4(11):a025650.
    View in: PubMed
    Score: 0.005
  50. Cancer cachexia update in head and neck cancer: Definitions and diagnostic features. Head Neck. 2015 Apr; 37(4):594-604.
    View in: PubMed
    Score: 0.004
  51. Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc Natl Acad Sci U S A. 2014 Mar 25; 111(12):4525-9.
    View in: PubMed
    Score: 0.004
  52. Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma. Mod Pathol. 2014 Sep; 27(9):1238-45.
    View in: PubMed
    Score: 0.004
  53. Protease nexin-1, a thrombin inhibitor, is regulated by interleukin-1 and dexamethasone in normal human fibroblasts. J Biol Chem. 1993 Sep 05; 268(25):18966-74.
    View in: PubMed
    Score: 0.004
  54. Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. Pancreas. 2013 Jul; 42(5):813-8.
    View in: PubMed
    Score: 0.004
  55. Regulation of skeletal muscle oxidative phenotype by classical NF-?B signalling. Biochim Biophys Acta. 2013 Aug; 1832(8):1313-25.
    View in: PubMed
    Score: 0.004
  56. The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas. Mod Pathol. 2013 Feb; 26(2):282-8.
    View in: PubMed
    Score: 0.004
  57. Report on the Myomatrix Conference April 22-24, 2012, University of Nevada, Reno, Nevada, USA. Neuromuscul Disord. 2013 Feb; 23(2):188-91.
    View in: PubMed
    Score: 0.004
  58. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. 2011; 6(7):e22538.
    View in: PubMed
    Score: 0.004
  59. IL-4R drives dedifferentiation, mitogenesis, and metastasis in rhabdomyosarcoma. Clin Cancer Res. 2011 May 01; 17(9):2757-66.
    View in: PubMed
    Score: 0.004
  60. Mass spectrometric detection of candidate protein biomarkers of cancer cachexia in human urine. Int J Oncol. 2010 Apr; 36(4):973-82.
    View in: PubMed
    Score: 0.003
  61. Zinc modulates the innate immune response in vivo to polymicrobial sepsis through regulation of NF-kappaB. Am J Physiol Lung Cell Mol Physiol. 2010 Jun; 298(6):L744-54.
    View in: PubMed
    Score: 0.003
  62. A novel role for IkappaBzeta in the regulation of IFNgamma production. PLoS One. 2009 Aug 26; 4(8):e6776.
    View in: PubMed
    Score: 0.003
  63. Bortezomib reverses a post-translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma. Pediatr Blood Cancer. 2009 Aug; 53(2):136-44.
    View in: PubMed
    Score: 0.003
  64. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2009 Aug 11; 106(32):13433-8.
    View in: PubMed
    Score: 0.003
  65. IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis. Cancer Res. 2008 Oct 15; 68(20):8351-60.
    View in: PubMed
    Score: 0.003
  66. Cachexia: a new definition. Clin Nutr. 2008 Dec; 27(6):793-9.
    View in: PubMed
    Score: 0.003
  67. Comparison of animal models for head and neck cancer cachexia. Laryngoscope. 2007 Dec; 117(12):2152-8.
    View in: PubMed
    Score: 0.003
  68. Apigenin blocks lipopolysaccharide-induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-kappaB through the suppression of p65 phosphorylation. J Immunol. 2007 Nov 15; 179(10):7121-7.
    View in: PubMed
    Score: 0.003
  69. Epstein-Barr virus-encoded dUTPase enhances proinflammatory cytokine production by macrophages in contact with endothelial cells: evidence for depression-induced atherosclerotic risk. Brain Behav Immun. 2008 Feb; 22(2):215-23.
    View in: PubMed
    Score: 0.003
  70. Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kappaB in adult T-cell leukemia/lymphoma. Leukemia. 2007 Aug; 21(8):1752-62.
    View in: PubMed
    Score: 0.003
  71. Cancer cachexia syndrome in head and neck cancer patients: Part II. Pathophysiology. Head Neck. 2007 May; 29(5):497-507.
    View in: PubMed
    Score: 0.003
  72. Cancer cachexia syndrome in head and neck cancer patients: part I. Diagnosis, impact on quality of life and survival, and treatment. Head Neck. 2007 Apr; 29(4):401-11.
    View in: PubMed
    Score: 0.003
  73. The molecular mechanisms of skeletal muscle wasting: implications for therapy. Surgeon. 2006 Oct; 4(5):273-83.
    View in: PubMed
    Score: 0.003
  74. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol. 2006 Apr 20; 24(12):1852-9.
    View in: PubMed
    Score: 0.003
  75. ASC directs NF-kappaB activation by regulating receptor interacting protein-2 (RIP2) caspase-1 interactions. J Immunol. 2006 Apr 15; 176(8):4979-86.
    View in: PubMed
    Score: 0.003
  76. NF-kappa B and I kappa B alpha are found in the mitochondria. Evidence for regulation of mitochondrial gene expression by NF-kappa B. J Biol Chem. 2003 Jan 31; 278(5):2963-8.
    View in: PubMed
    Score: 0.002
  77. Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol. 2002 Apr 29; 157(3):429-40.
    View in: PubMed
    Score: 0.002
  78. Suppression of tumor necrosis factor-mediated apoptosis by nuclear factor kappaB-independent bone morphogenetic protein/Smad signaling. J Biol Chem. 2001 Oct 19; 276(42):39259-63.
    View in: PubMed
    Score: 0.002
  79. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem. 2001 Jun 22; 276(25):22382-7.
    View in: PubMed
    Score: 0.002
  80. Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol. 2001 Jan 08; 152(1):87-96.
    View in: PubMed
    Score: 0.002
  81. Levodopa-carbidopa. Aust Nurses J. 1980 May; 9(10):28-9.
    View in: PubMed
    Score: 0.002
  82. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene. 2000 Feb 24; 19(9):1123-31.
    View in: PubMed
    Score: 0.002
  83. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol. 1999 Sep; 19(9):5923-9.
    View in: PubMed
    Score: 0.002
  84. IkappaBalpha gene transfer is cytotoxic to squamous-cell lung cancer cells and sensitizes them to tumor necrosis factor-alpha-mediated cell death. Am J Respir Cell Mol Biol. 1999 Aug; 21(2):238-45.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.